Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
PMV Pharmaceuticals, Inc
AstraZeneca
National Institutes of Health Clinical Center (CC)
Kivu Bioscience Inc.
NeoImmuneTech
BeOne Medicines
Neonc Technologies, Inc.
NiKang Therapeutics, Inc.
MacroGenics
MacroGenics
AstraZeneca
SystImmune Inc.
SN BioScience
Radiopharm Theranostics, Ltd
ImmunityBio, Inc.
VM Oncology, LLC
GV20 Therapeutics
DualityBio Inc.
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Incyte Corporation
Janux Therapeutics
NiKang Therapeutics, Inc.
Novelty Nobility, Inc.
Merck Sharp & Dohme LLC
Pfizer
Hoffmann-La Roche
Incyte Corporation
University of Virginia
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
Marengo Therapeutics, Inc.
Shanghai Public Health Clinical Center
TransThera Sciences (Nanjing), Inc.
NRG Oncology
Hutchmed
Stanford University
Seagen Inc.
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Cybrexa Therapeutics
Sotio Biotech Inc.
Cyteir Therapeutics, Inc.
Carisma Therapeutics Inc
Tasly Biopharmaceuticals Co., Ltd.
Sellas Life Sciences Group
Vincerx Pharma, Inc.
Salubris Biotherapeutics Inc